文献速递儿科与产科急症重症综合管理与镇静镇痛心脑血管急症

儿童多系统炎症综合征的初始治疗与结局

Multisystem Inflammatory Syndrome in Children - Initial Therapy and Outcomes.
PubMed 文献 · N Engl J Med · 2021-06-16
一句话结论在MIS-C住院患儿中,初始静脉注射免疫球蛋白(IVIG)联合糖皮质激素较单用IVIG与第2天及之后心血管功能障碍风险更低相关(17% vs 31%;RR 0.56;95%CI 0.34–0.94)。

该研究分析2020年3月15日至10月31日美国58家医院收治的21岁以下MIS-C住院患儿监测数据,采用倾向评分匹配和逆概率加权评估初始IVIG联合糖皮质激素与单用IVIG的有效性,主要终点为第2天及之后的心血管功能障碍(左心室功能障碍或需使用血管升压药的休克复合终点)。匹配分析显示,联合治疗组(103例)第2天及之后心血管功能障碍风险低于单用IVIG组(103例)(17% vs 31%;RR 0.56;95%CI 0.34–0.94),左心室功能障碍(8% vs 17%;RR 0.46;95%CI 0.19–1.15)和需血管升压药的休克(13% vs 24%;RR 0.54;95%CI 0.29–1.00)风险亦较低,辅助治疗使用更少(34% vs 70%;RR 0.49;95%CI 0.36–0.65),发热风险无差异(31% vs 40%;RR 0.78;95%CI 0.53–1.13);逆概率加权分析证实上述结果。作者认为,MIS-C患儿初始IVIG联合糖皮质激素较单用IVIG与更低的新发或持续心血管功能障碍风险相关。

要点

  • MIS-C患儿初始IVIG联合糖皮质激素较单用IVIG与第2天及之后心血管功能障碍风险更低相关(17% vs 31%;RR 0.56;95%CI 0.34–0.94)。
  • 联合治疗组需血管升压药的休克风险较单用IVIG组更低(13% vs 24%;RR 0.54;95%CI 0.29–1.00)。
  • 联合治疗组左心室功能障碍风险较单用IVIG组更低(8% vs 17%;RR 0.46;95%CI 0.19–1.15)。
  • 联合治疗组辅助治疗(第0天未用糖皮质激素者加用糖皮质激素、生物制剂或第二剂IVIG)使用更少(34% vs 70%;RR 0.49;95%CI 0.36–0.65)。
  • 联合治疗组与单用IVIG组发热风险无显著差异(31% vs 40%;RR 0.78;95%CI 0.53–1.13)。

适用人群与场景

  • 美国58家医院收治的21岁以下MIS-C住院患儿,入院时间在2020年3月15日至2020年10月31日之间。
  • 518例接受至少一种免疫调节治疗的MIS-C患儿,中位年龄8.7岁,75%既往健康,9例死亡。

研究设计与关键结果

  • 研究类型:基于监测数据的倾向评分匹配和逆概率加权分析;样本量518例;58家美国医院;人群为21岁以下MIS-C住院患儿。
  • 主要终点:第2天及之后心血管功能障碍(左心室功能障碍或需使用血管升压药的休克复合终点);倾向评分匹配分析中,初始IVIG联合糖皮质激素组(103例)发生率17% vs 单用IVIG组(103例)31%,风险比0.56(95%CI 0.34–0.94)。
  • 次要终点左心室功能障碍:联合治疗组8% vs 单用IVIG组17%,风险比0.46(95%CI 0.19–1.15)。
  • 次要终点需血管升压药的休克:联合治疗组13% vs 单用IVIG组24%,风险比0.54(95%CI 0.29–1.00)。
  • 次要终点第1天及之后辅助治疗(第0天未用糖皮质激素者加用糖皮质激素、生物制剂或第二剂IVIG):联合治疗组34% vs 单用IVIG组70%,风险比0.49(95%CI 0.36–0.65)。
  • 次要终点第2天及之后持续或复发性发热:联合治疗组31% vs 单用IVIG组40%,风险比0.78(95%CI 0.53–1.13)。
  • 逆概率加权分析证实倾向评分匹配分析的结果。

证据类型、等级与局限

  • 证据类型:基于监测数据的观察性研究(倾向评分匹配和逆概率加权分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在MIS-C儿童和青少年中,初始IVIG联合糖皮质激素较单用IVIG与更低的新发或持续心血管功能障碍风险相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The assessment of real-world effectiveness of immunomodulatory medications for multisystem inflammatory syndrome in children (MIS-C) may guide therapy.

METHODS: We analyzed surveillance data on inpatients younger than 21 years of age who had MIS-C and were admitted to 1 of 58 U.S. hospitals between March 15 and October 31, 2020. The effectiveness of initial immunomodulatory therapy (day 0, indicating the first day any such therapy for MIS-C was given) with intravenous immune globulin (IVIG) plus glucocorticoids, as compared with IVIG alone, was evaluated with propensity-score matching and inverse probability weighting, with adjustment for baseline MIS-C severity and demographic characteristics. The primary outcome was cardiovascular dysfunction (a composite of left ventricular dysfunction or shock resulting in the use of vasopressors) on or after day 2. Secondary outcomes included the components of the primary outcome, the receipt of adjunctive treatment (glucocorticoids in patients not already receiving glucocorticoids on day 0, a biologic, or a second dose of IVIG) on or after day 1, and persistent or recurrent fever on or after day 2.

RESULTS: A total of 518 patients with MIS-C (median age, 8.7 years) received at least one immunomodulatory therapy; 75% had been previously healthy, and 9 died. In the propensity-score-matched analysis, initial treatment with IVIG plus glucocorticoids (103 patients) was associated with a lower risk of cardiovascular dysfunction on or after day 2 than IVIG alone (103 patients) (17% vs. 31%; risk ratio, 0.56; 95% confidence interval [CI], 0.34 to 0.94). The risks of the components of the composite outcome were also lower among those who received IVIG plus glucocorticoids: left ventricular dysfunction occurred in 8% and 17% of the patients, respectively (risk ratio, 0.46; 95% CI, 0.19 to 1.15), and shock resulting in vasopressor use in 13% and 24% (risk ratio, 0.54; 95% CI, 0.29 to 1.00). The use of adjunctive therapy was lower among patients who received IVIG plus glucocorticoids than among those who received IVIG alone (34% vs. 70%; risk ratio, 0.49; 95% CI, 0.36 to 0.65), but the risk of fever was unaffected (31% and 40%, respectively; risk ratio, 0.78; 95% CI, 0.53 to 1.13). The inverse-probability-weighted analysis confirmed the results of the propensity-score-matched analysis.

CONCLUSIONS: Among children and adolescents with MIS-C, initial treatment with IVIG plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone. (Funded by the Centers for Disease Control and Prevention.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Son MBF, Murray N, Friedman K, et al. Multisystem Inflammatory Syndrome in Children - Initial Therapy and Outcomes. N Engl J Med. 2021. PMID: 34133855. doi:10.1056/NEJMoa2102605

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。